Skip to main content
SpringerLink
Log in

Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy

  • Chapter
  • First Online:
Hydroxychloroquine and Chloroquine Retinopathy

  • 1334 Accesses

Abstract

The prevalence of 4-aminoquinoline retinopathy has not been scientifically determined, but flawed data indicate that the prevalence of chloroquine retinopathy is higher than the prevalence of hydroxychloroquine retinopathy. In patients who are dosed properly according to ideal body weight, the prevalence of hydroxychloroquine retinopathy is much less than 1 %. The prevalence of chloroquine retinopathy in properly dosed patients is unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

4AQR:

4-Aminoquinoline retinopathy

4AQs:

4-Aminoquinolines (chloroquine and hydroxychloroquine)

ABW:

Actual body weight

AG:

Amsler grid

C:

Chloroquine

CE:

Clinical examination

CT:

Cone thresholds

CV:

Color vision testing

DA:

Dark adaptation test

EOG:

Electrooculogram

ERG:

Electroretinogram

FP:

Fundus photography

HC:

Hydroxychloroquine

IBW:

Ideal body weight

KVF:

Kinetic visual field testing

LPT:

Light photo stress test

NG:

Not given

RA:

Rheumatoid arthritis

RPE:

Retinal pigment epithelium

SAP:

Static automated perimetry

SLE:

Systemic lupus erythematosus

TS:

Tangent screen testing

VA:

Visual acuity

References

  1. Rothermich NO. Coming catastrophes with chloroquine? Ann Intern Med. 1964;61:1203–5.

    Article  CAS  PubMed  Google Scholar 

  2. Wallace DJ. Antimalarials-the ‘real’ advance in lupus. Lupus. 2001;10:385–7.

    Article  CAS  PubMed  Google Scholar 

  3. Bunch TW, O’Duffy JD. Disease modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc. 1980;55:161–79.

    CAS  PubMed  Google Scholar 

  4. Neubauer AS, Samari-Kermani K, Schaller U, Welge-Luben U, Rudolph G, Berninger T. Detecting chloroquine retinopathy: electro-oculogram versus color vision. Br J Ophthalmol. 2003;87:902–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75:25–34.

    Article  CAS  PubMed  Google Scholar 

  6. Lawrence JS. Prevalence of rheumatoid arthritis. Ann Rheum Dis. 1961;20:11–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130:461–9.

    Article  CAS  PubMed  Google Scholar 

  8. Lai TYY, Ngai JWS, Chan WM, Lam DSC. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol. 2006;112:177–87.

    Article  PubMed  Google Scholar 

  9. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133:649–56.

    Article  CAS  PubMed  Google Scholar 

  10. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41:793–800.

    Article  CAS  PubMed  Google Scholar 

  11. Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death of SLE patients in FInland. Scand J Rheumatol. 1985;14:43–6.

    Article  CAS  PubMed  Google Scholar 

  12. Elder M, Rahman AMA. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol. 2006;124:1729–33.

    Article  PubMed  Google Scholar 

  13. Almony A, Garg S, Peters RK, Mamet R, Tsong J, Shibuya B, Kitridou R, Sadun AA. Threshold amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. Br J Ophthalmol. 2005;89:569–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine—a reappraisal. Ophthalmology. 2003;110:1321–6.

    Article  PubMed  Google Scholar 

  15. Tobin DR, Krohel G, Rynes RI. Hydroxychloroquine-seven-year experience. Arch Ophthalmol. 1982;100:81–3.

    Article  CAS  PubMed  Google Scholar 

  16. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84.

    Article  CAS  Google Scholar 

  17. Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol. 1967;64:245–52.

    CAS  PubMed  Google Scholar 

  18. Rynes RI, Krohel G, Falbo A, Reinecke RD, Wolfe B, Bartholomew LE. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum. 1979;22:832–6.

    Article  CAS  PubMed  Google Scholar 

  19. Mantyjarvi M. Hydroxychloroquine treatment and the eye. Scand J Rheumatol. 1985;14:171–4.

    Article  CAS  PubMed  Google Scholar 

  20. Levy GD, Munz SJ, Paschal J, Cohen HB, Prince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40:1482–6.

    Article  CAS  PubMed  Google Scholar 

  21. Bergholz R, Schroeter J, Ruther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol. 2010;94:1637–42.

    Article  CAS  PubMed  Google Scholar 

  22. Heravian J, Saghafi M, Shoeibi N, Hassanzadeh S, Shakeri MT, Sharepoor M. A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in the early detection of ocular toxicity from hydroxychloroquine. Int Ophthalmol. 2011;31:283–9.

    Article  PubMed  Google Scholar 

  23. Bonanomi MT, Dantas NC, Medeiros FA. Retinal nerve fiber layer thickness measurements in patients using chloroquine. Clin Exp Ophthalmol. 2006;34:130–6.

    Article  Google Scholar 

  24. Percival SPB, Behrman J. Ophthalmological safety of chloroquine. Br J Ophthalmol. 1969;53:101–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Fleck BW, Bell AL, Mitchell JD, Thomson BJ, Hurst NP, Nuki G. Screening for antimalarial maculopathy in rheumatology clinics. Br Med J. 1985;291:782–5.

    Article  CAS  Google Scholar 

  26. Tanga L, Centofanti M, Oddone F, Parravano M, Parisi V, Ziccardi L, Kroegler B, Perricone R, Manni G. Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine. Graefes Arch Clin Exp Ophthalmol. 2011;249:715–21.

    Article  CAS  PubMed  Google Scholar 

  27. Bartel PR, Roux P, Robinson E, Anderson IF, Brighton SW, Van der Hoven HJ, Becker PJ. Visual function and long-term chloroquine treatment. S Afr Med J. 1994;84:32–4.

    CAS  PubMed  Google Scholar 

  28. Bray VJ, Enzenauer RJ, Enzenauer RW, West SG. Antimalarial toxicity in rheumatic disease. J Clin Rheumatol. 1998;4:168–9.

    Article  CAS  PubMed  Google Scholar 

  29. Bailey LA, Hiltz JW. Ocular complications of chloroquine therapy. Can Med Assoc J. 1965;6:508–13.

    Google Scholar 

  30. Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis. 2010;13:e11–5.

    Article  PubMed  Google Scholar 

  31. Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol. 1999;26:808–15.

    CAS  PubMed  Google Scholar 

  32. Wasko MCM, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187–93.

    Article  CAS  PubMed  Google Scholar 

  33. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis. 1997;56:188–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol. 1985;12:692–4.

    CAS  PubMed  Google Scholar 

  35. Voipio H. Incidence of chloroquine retinopathy. Acta Ophthalmol (Copenh). 1966;44:349–54.

    Article  CAS  Google Scholar 

  36. Marks JS, Power BJ. Is chloroquine obsolete in treatment of rheumatic disease? Lancet. 1979;1:371–3.

    Article  CAS  PubMed  Google Scholar 

  37. Scherbel AL, Mackenzie AH, Nousek JE, Atdjian M. Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy-A study of 741 patients treated with and without chloroquine drugs. N Engl J Med. 1965;273:360–6.

    Article  CAS  PubMed  Google Scholar 

  38. Henkind P, Rothfield NF. Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med. 1963;269:434–9.

    Article  Google Scholar 

  39. Banks CN. Melanin: blackguard or red herring? Another look at chloroquine retinopathy. Aust N Z J Ophthalmol. 1987;15:365–70.

    Article  CAS  PubMed  Google Scholar 

  40. Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. Progression of hydroxychloroquine toxic effects after drug therapy cessation. New evidence from multimodal imaging. Arch Ophthalmol. 2013;131:1187–97.

    Google Scholar 

  41. Jekel JF, Elmore JG, Katz DL. Epidemiology, biostatistics, and preventive medicine. Philadelphia: WB Saunders; 1996. p. 216–7.

    Google Scholar 

  42. Vitale S, Maguire MG, Murphy RP, Hiner CJ, Rourke L, Sackett C, Patz A. Clinically significant macular edema in type I diabetes. Ophthalmology. 1995;102:1170–6.

    Article  CAS  PubMed  Google Scholar 

  43. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med. 1988;85:23–9.

    Article  CAS  PubMed  Google Scholar 

  44. Sundelin SP, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 2002;110:481–9.

    Google Scholar 

  45. Easterbrook M. Clinical characteristics of hydroxychloroquine retinopathy. Evid Based Ophthalmol. 2011;12:132–3.

    Google Scholar 

  46. Xiaoyun MA, Dongyi HE, Linping HE. Assessing chloroquine toxicity in RA patients using retinal nerve fiber layer thickness, multifocal electroretinography and visual field test. Br J Ophthalmol. 2010;94:1632–6.

    Article  CAS  PubMed  Google Scholar 

  47. Shinjo SK, Junior OOM, Tizziani VAP, Morita C, Kochen JAL, Takahashi WY, Laurindo IMM. Chloroquine-induced bull’s eye maculopathy in rheumatoid arthritis: related to disease duration? Clin Rheumatol. 2007;26:1248–53.

    Article  PubMed  Google Scholar 

  48. Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, Okada M. Use of hydroxychloroquine in Japan. J Rheumatol. 2012;39:1296.

    Article  PubMed  Google Scholar 

  49. Houpt JB. A rheumatologist’s verdict on the safety of chloroquine versus hydroxychloroquine. Liability in off-label prescribing. J Rheumatol. 1999;26:1864–6.

    CAS  PubMed  Google Scholar 

  50. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109:1377–82.

    Article  PubMed  Google Scholar 

  51. Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12:294–304.

    CAS  PubMed  Google Scholar 

  52. Bourke B, Jones S, Rajammal AK, Silman A, Smith R. Hydroxychloroquine and ocular toxicity recommendations on screening. The Royal College of Ophthalmologists; 2009. p. 1–9. www.rcophth.ac.uk. Accessed 13 Apr 2014.

  53. Blythe C, Lane C. Hydroxychloroquine retinopathy: is screening necessary? Intensive screening is not necessary at normal doses. Br Med J. 1998;316:716–7.

    Article  Google Scholar 

  54. Coyle JT. Hydroxychloroquine retinopathy [letter to the Editors]. Ophthalmology. 2001;108:243–4.

    Article  CAS  PubMed  Google Scholar 

  55. Albert DA, Debois LKL, Lu KF. Antimalarial ocular toxicity, a critical appraisal. J Clin Rheumatol. 1998;4:57–62.

    Article  CAS  PubMed  Google Scholar 

  56. Fielder A, Graham E, Jones S, Silman A, Tullo A. Royal college of ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Eye. 1998;12:907–9.

    Article  PubMed  Google Scholar 

  57. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 1999;140:3–7.

    Article  CAS  PubMed  Google Scholar 

  58. Cox NH, Paterson WD. Ocular toxicity of antimalarials in dermatology: a survey of current practice. Br J Dermatol. 1994;131:878–82.

    Article  CAS  PubMed  Google Scholar 

  59. Carr RE, Henkind P, Rothfield N, Siegel IM. Ocular toxicity of antimalarial drugs-long-term follow-up. Am J Ophthalmol. 1968;66:738–44.

    CAS  PubMed  Google Scholar 

  60. Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol (Copenh). 1966;44:335–8.

    Article  CAS  Google Scholar 

  61. Fuld H. Retinopathy following chloroquine therapy. Lancet. 1959;2:617–8.

    Article  Google Scholar 

  62. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum. 1987;16:206–21.

    Article  CAS  PubMed  Google Scholar 

  63. Spalton DJ, Roe GMV, Hughes GRV. Hydroxychloro-quine, dosage parameters and retinopathy. Lupus. 1993;2:355–8.

    Google Scholar 

  64. Adam MK, Covert DJ, Stepien KE, Han DP. Quantitative assessment of the 103 hexagon multifocal electroretinogram in detection of hydroxychloroquine retinal toxicity. Br J Ophthalmol. 2012;96:723–9.

    Article  PubMed  Google Scholar 

  65. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129:30–9.

    Article  CAS  PubMed  Google Scholar 

  66. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991;23:292–6.

    CAS  PubMed  Google Scholar 

  67. Semmer AE, Lee MS, Harrison AR, Olsen TW. Hydroxychloroquine retinopathy screening. Br J Ophthalmol. 2008;92:1653–5.

    Article  CAS  PubMed  Google Scholar 

  68. Blomquist PH, Chundru RK. Screening for hydroxychloroquine toxicity by Texas ophthalmologists. J Rheumatol. 2002;29:1665–70.

    PubMed  Google Scholar 

  69. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol. 1993;25:385–8.

    CAS  PubMed  Google Scholar 

  70. Thorne JE, Maguire AM. Retinopathy after long term, standard doses of hydroxychloroquine. Br J Ophthalmol. 1999;83:1201–2.

    Article  CAS  PubMed  Google Scholar 

  71. Bienfang D, Coblyn JS, Liang MH, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol. 2000;27:2703–6.

    CAS  PubMed  Google Scholar 

  72. Easterbrook M. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol. 1999;26:1866–7.

    CAS  PubMed  Google Scholar 

  73. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996;55:187–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Payne JF, Hubbard III GB, Aaberg Sr TM, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol. 2010;95:245–50.

    Article  PubMed  Google Scholar 

  75. Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol. 2012;6:377–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122:973–81.

    Article  CAS  PubMed  Google Scholar 

  77. Browning DJ. Impact of the revised American academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418–28.

    Article  PubMed  Google Scholar 

  78. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47:3531–8.

    Article  PubMed  Google Scholar 

  79. Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med. 1983;75:35–9.

    Article  CAS  PubMed  Google Scholar 

  80. Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1992;51:1318–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5:S16–22.

    Article  CAS  PubMed  Google Scholar 

  82. Percival SPB, Meanock I. Chloroquine: ophthalmological safety and clinical assessment in rheumatoid arthritis. Br Med J. 1968;3:579–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  83. Flach AJ. Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine. Trans Am Ophthalmol Soc. 2007;105:191–7.

    PubMed Central  PubMed  Google Scholar 

  84. Sfikakis PP, Mavrikakis M. Ophthalmologic monitoring for antimalarial toxicity. J Rheumatol. 2004;31:1011–2.

    PubMed  Google Scholar 

  85. Nebbioso M, Grenga R, Karavitas P. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. J Ocul Pharmacol Ther. 2009;25:249–58.

    Article  CAS  PubMed  Google Scholar 

  86. Elman A, Gullberg R, Nillson E, Rendahl I, Wachtmeister L. Choroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol. 1975;5:161–6.

    Article  Google Scholar 

  87. Mackenzie AH. An appraisal of chloroquine. Arthritis Rheum. 1970;13:280–91.

    Article  CAS  PubMed  Google Scholar 

  88. Hobbs HE, Eadie SP, Somerville F. Ocular lesions after treatment with chloroquine. Br J Ophthalmol. 1961;45:284–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Butler I. Retinopathy following the use of chloroquine and allied substances. Ophthalmologica. 1965;149:204–8.

    Article  CAS  PubMed  Google Scholar 

  90. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75:40–5.

    Article  CAS  PubMed  Google Scholar 

  91. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye. 1990;4:572–6.

    Article  PubMed  Google Scholar 

  92. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol. 1987;104:139–44.

    CAS  PubMed  Google Scholar 

  93. Frenkel M. Safety of hydroxychloroquine. Arch Ophthalmol. 1982;100:841.

    Article  CAS  PubMed  Google Scholar 

  94. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol. 1992;2:237–9.

    Google Scholar 

  95. Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med. 1983;75:52–6.

    Article  CAS  PubMed  Google Scholar 

  96. Patty L, Wu C, Torres M, Azen S, Varma R, Los Angeles Latino Eye Study Group. Validity of self-reported eye disease and treatment in a population-based study: the Los Angeles Latino Eye Study. Ophthalmology. 2012;119:1725–30.

    Article  PubMed Central  PubMed  Google Scholar 

  97. Linton KL, Klein BE, Klein R. The validity of self-reported and surrogate-reported cataract and age-related macular degeneration in the Beaver Dam Eye Study. Am J Epidemiol. 1991;134:1438–46.

    CAS  PubMed  Google Scholar 

  98. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–22.

    Article  PubMed  Google Scholar 

  99. Spalton DJ. Retinopathy and antimalarial drugs-the British experience. Lupus. 1996;5:S70–2.

    Article  CAS  PubMed  Google Scholar 

  100. Blomquist PH. Screening for hydroxychloroquine toxicity. Comp Ophthalmol Update. 2000;1:245–50.

    Google Scholar 

  101. Rodriguez-Padilla JA, Hedges III TR, Monson B, Srinivasan V, Wojtkowski M, Reichel E, Duker JS, Schuman JS, Fujimoto JG. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125:775–80.

    Article  PubMed Central  PubMed  Google Scholar 

  102. Marmor MF. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am J Ophthalmol. 2005;140:894–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC, USA

    David J. Browning

Authors
  1. David J. Browning
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Browning, D.J. (2014). Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy. In: Hydroxychloroquine and Chloroquine Retinopathy. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0597-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0597-3_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0596-6

  • Online ISBN: 978-1-4939-0597-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation